CAS 2169919-21-3

SNDX-5613

CAS: 2169919-21-3

Revumenib (SNDX-5613) is a potent and selective oral inhibitor of menin-KMT2A interaction.Cost-effective and quality-assured.

Formula: C₃₂H₄₇FN₆O₄S

Purezza: 99.12% - 99.97%

Colore e forma: Yellow Solid

Peso molecolare: 630.82

Ref: TM-T12943

SNDX-5613

CAS: 2169919-21-3

SNDX-5613

Formula: C₃₂H₄₇FN₆O₄S

Purezza: ≥98%

Colore e forma: Solid

Peso molecolare: 630.82

Ref: 54-BUP04627

Revumenib

CAS: 2169919-21-3

Formula: C₃₂H₄₇FN₆O₄S

Peso molecolare: 630.82

Ref: 4Z-R-171001

Revumenib

CAS: 2169919-21-3

N-Ethyl-2-((4-(7-((trans-4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide

Formula: C₃₂H₄₇FN₆O₄S

Purezza: 98%

Peso molecolare: 630.82

Ref: IN-DG01301059

SNDX-5613

CAS: 2169919-21-3

Revumenib, also known as SNDX-5613, is a potent and selective inhibitor of the interaction between menin and the lysine methyltransferase 2A (KMT2A). In recent studies, it has shown promising results in targeting the epigenetic regulator KMT2A, which seems to be involved in certain leukaemia subtypes.

Formula: C₃₂H₄₇FN₆O₄S

Purezza: Min. 95%

Peso molecolare: 630.8 g/mol

Ref: 3D-ULD91921

Revumenib

CAS: 2169919-21-3

Formula: C₃₂H₄₇FN₆O₄S

Peso molecolare: 630.82

Ref: ST-EA-CP-R68000